Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study

Aim: The aim of this study was to compare the efficacy and safety of α1‐adrenoceptor (α1‐AR) antagonist monotherapy with combination therapy using α1‐AR antagonist and anticholinergic agent for benign prostatic hyperplasia (BPH) with storage symptoms as the chief complaint. Methods: In this prospect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of urology 2006-10, Vol.13 (10), p.1280-1285
Hauptverfasser:	MARUYAMA, OSAMU, KAWACHI, YOSHIO, HANAZAWA, KISABURO, KOIZUMI, KAZUO, YAMASHITA, RYO, SUGIMURA, SOSUKE, HONDA, SHIN-ICHI, SUGIYAMA, YOSHIKI, SAITOH, TOSHIHIKO, NOTO, KENSHO
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic alpha-Antagonists - therapeutic use Aged anticholinergic agent benign prostatic hyperplasia Benzilates - therapeutic use Cholinergic Antagonists - therapeutic use Drug Therapy, Combination Follow-Up Studies Humans Male Mandelic Acids - therapeutic use naftopidil Naphthalenes - therapeutic use Piperazines - therapeutic use Prospective Studies Prostatic Hyperplasia - complications storage symptom Treatment Outcome Urinary Retention - drug therapy Urinary Retention - etiology Urinary Retention - physiopathology Urodynamics - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!